Liver transplantation (LT) is a curative treatment in early and intermediate hepatocellular carcinoma (HCC) after downstaging with locoregional therapies (LRT). Tumor response to immune check-point inhibitors may extend LT eligibility to intermediate and advanced stages.
Journal of Hepatology published a clinical update in Research Highlights on 26 Feb 2026.
The item focuses on Efficacy of liver transplantation after response to atezolizumab-bevacizumab downstaging of intermediate and advanced hepatocellular carcinoma (ImmunoXXL).
Review the original article for the full source wording and details.